查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1673816

製药和生物技术临床前合作条款和协议（2020-2025年）

Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2020-2025
出版日期: | 出版商: Current Partnering | 英文 1500+ Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

本报告研究了製药和生物技术行业内的临床前合作条款和协议，并提供了全面的资料驱动分析，说明公司如何以及为何签订临床前合作协议，以及这些协议所依据的财务和战略条款。本报告还深入洞察了製药和生物技术产业早期联盟的结构、谈判动态和财务考量。

在临床前阶段，授权协议通常授予被授权人进一步开发授权人的候选药物或技术的权利或选择权。这些协议通常是多方面的，可能从合作研究和开发开始，最终达成商业化协议。

本报告详细分析了医疗保健领域最新的临床前交易，以帮助公司了解市场趋势，评估竞争对手的交易结构，并最佳化自己的谈判策略。

本报告提供：

  • 2020年及以后生物製药产业临床前交易趋势分析
  • 了解财务结构，包括预付款、里程碑付款和特许权使用费
  • 实际临床前合约案例研究
  • 可查阅超过 1,670 例临床前阶段病例
  • 2020年及以后最活跃的临床前交易者简介
  • 对最高价值临床前交易的详细分析

目录

执行摘要

第1章 简介

第2章 为什么各公司要在临床前化合物上合作？

  • 临床前合作的作用
    • 临床前阶段的许可
    • 临床前阶段的许可
  • 区分发现、临床前和临床阶段的交易
  • 为什么要签临床前合作协议？
    • 许可方为何参与临床前交易
    • 为什么被授权人要达成临床前交易
  • 临床前合作交易的未来

第3章 临床前交易策略与结构

  • 公司在什么阶段进行合作？
    • 製药/生技领域的早期合作
    • 製药/生技联盟
  • 早期与晚期伙伴关係：风险与成本
  • 各公司在临床前合作上花了多少钱？
  • 纯合作协议与多部分合作协议
  • 纯许可合约结构
    • 纯临床前许可协议范例
    • 个案研究
  • 多组分临床前合作协议
    • 多组分临床前条款范例
    • 个案研究

第4章 临床前合作关係的付款策略

  • 临床前付款策略
  • 付款方式
    • 标题
    • 预付
    • 贷款
    • 可转换贷款
    • 公平
    • 研发资金
    • 许可证费用
    • 里程碑
    • 版税
    • 现金
    • 选择

第5章 临床前交易趋势

  • 临床前阶段合作 1年以上
  • 依交易类型划分的临床前合作伙伴关係
  • 依疾病类型划分的临床前合作
  • 依技术类型划分的临床前合作伙伴关係
  • 最活跃的企业临床前合作

第6章 临床前合作付款条款

  • 临床前阶段付款条款指南
    • 预付
    • 里程碑
    • 版税
  • 临床前付款条款：交易资料分析
    • 公开资料
    • 调查资料
  • 付款条件分析
    • 临床前阶段主要资料
    • 临床前合约的预付款
    • 临床前合约的里程碑付款
    • 临床前专利使用费率

第7章 关键临床前交易

  • 依金额的顶级临床前交易

第8章 现阶段前25名交易者

  • 25 位最活跃的临床前交易者

第9章 临床前合作协议目录

  • 2020年至2025年合约的临床前阶段交易

第10章 临床前交易（依开发阶段划分）

  • 依临床前阶段划分的交易

附录

简介目录
Product Code: CP2057

Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech (2020-2025)

The Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2020-2025 report provides a comprehensive, data-driven analysis of how and why companies enter preclinical-stage partnering agreements, as well as the key financial and strategic terms shaping these partnerships. This essential industry resource delivers unparalleled insights into the structure, negotiation dynamics, and financial considerations that define early-stage pharmaceutical and biotech collaborations.

At the preclinical stage, licensing agreements typically grant the licensee exclusive rights or options to develop a licensor's drug candidate or technology. These agreements are often multifaceted, beginning with collaborative R&D efforts and potentially culminating in commercialization agreements.

This report provides detailed intelligence on the latest preclinical-stage agreements in the healthcare sector, helping companies evaluate market trends, optimize negotiation strategies, and benchmark deal structures.

A Must-Have Resource for Biotech and Pharma Dealmakers

The Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech (2020-2025) report is an indispensable resource for business development, legal, and financial professionals involved in biopharma dealmaking.

With comprehensive insights, a vast deal database, and direct access to contract documents, this report serves as the ultimate tool for:

  • Benchmarking deal structures and financial terms
  • Optimizing negotiation strategies
  • Assessing potential partners' flexibility
  • Identifying trends in preclinical-stage partnerships
  • Why This Report is Essential for Dealmakers
  • Understanding a potential partner's negotiation flexibility and deal structures is critical when entering preclinical-stage partnerships. While headline financial figures (e.g., upfront payments, milestones, royalties) are important, contract documents reveal the precise triggers and conditions for these payments-details that are often missing from press releases and traditional deal databases.
  • This report provides a comprehensive listing of over 1,670 preclinical-stage deals announced since 2020, including financial terms where available. Additionally, it includes direct links to online deal records, along with publicly available contract documents submitted to the SEC.
  • By analyzing these agreements, companies can gain critical insights to refine deal strategies, assess partner flexibility, and structure competitive agreements.
  • Comprehensive Analysis of Preclinical-Stage Partnering Trends

The first chapters of this report offer a detailed orientation to preclinical-stage deal-making, including:

Chapter 1 - Introduction to the report

Chapter 2 - Why companies engage in preclinical-stage partnerships

Chapter 3 - Strategic approaches and deal structures, with case studies

Chapter 4 - Payment strategies, including upfronts, milestones, and royalties

Chapter 5 - Analysis of preclinical-stage deal activity (2020-2025), categorized by year, stage of development, therapeutic area, technology type, and key dealmakers

Chapter 6 - In-depth financial analysis of headline values, upfront payments, milestone triggers, and royalty rates

Chapter 7 - A review of the leading preclinical-stage deals by headline value

Chapter 8 - Profiles of the top 25 most active preclinical-stage dealmakers

Chapter 9 - A database of preclinical-stage partnering agreements, including contract documents where available

Chapter 10 - A comprehensive directory of all preclinical-stage deals announced since 2020

  • Key Benefits of the Report

This must-have industry resource provides exclusive insights to help companies assess, structure, and negotiate their own preclinical-stage partnerships. Key benefits include:

  • Time-Saving Market Intelligence - Eliminate the need for manual research with ready-to-use insights on industry trends and deal structures.
  • Unmatched Financial Data Access - Gain exclusive insight into headline values, upfront payments, milestone structures, and royalty terms to optimize negotiations.
  • Comprehensive Deal Database - Access over 1,670 preclinical-stage agreements, including contract documents where available.
  • Deep-Dive into Industry Leaders - Analyze actual preclinical-stage deals entered into by the top 25 global pharma and biotech companies, alongside emerging players.
  • Strategic Case Studies & Deal Analysis - Examine real-world deal structures and negotiation strategies to enhance your own business development approach.
  • High-Value Deal Identification - Pinpoint the most lucrative preclinical-stage deals signed since 2020, gaining insight into premium industry transactions.
  • Profile the Most Active Dealmakers - Identify key players driving preclinical-stage collaborations, ensuring you engage with the right partners.
  • Full Deal Listings & Categorization - Navigate a complete A-Z listing of preclinical-stage agreements, categorized by company, development phase, deal type, therapeutic area, and technology focus.
  • Negotiate with Confidence - Understand the key terms and conditions agreed upon in previous deals, helping you structure optimal agreements.
  • Robust Due Diligence Support - Conduct data-backed assessments to determine the viability and competitiveness of your proposed deal terms.
  • Scope of the Report

The Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech (2020-2025) report provides:

  • Trends in preclinical-stage dealmaking in the biopharma industry since 2020
  • Detailed deal structures, including upfront, milestone, and royalty terms
  • Case studies of real-life preclinical-stage agreements
  • Access to over 1,670 preclinical-stage deals, with contract records where available
  • Profiles of the most active preclinical-stage dealmakers since 2020
  • Analysis of the highest-value preclinical-stage deals

Each deal record is indexed by:

  • Company (A-Z)
  • Headline Value
  • Deal Type
  • Specific Therapy Focus
  • Technology Focus
  • Critical Questions Answered

By analyzing actual contract agreements where available, this report provides definitive answers to critical questions such as:

  • What specific rights are granted in each agreement?
  • What exclusivity terms apply?
  • How is the deal structured financially? (Upfronts, milestones, royalties)
  • Who controls development, manufacturing, and commercialization?
  • How are intellectual property rights handled?
  • What are the termination conditions for the agreement?
  • What dispute resolution mechanisms are in place?
  • How are confidentiality and publication rights managed?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Why do companies partner preclinical stage compounds?

  • 2.1. Introduction
  • 2.2. The role of preclinical stage partnering
    • 2.2.1. In-licensing at preclinical stage
    • 2.2.2. Out-licensing at preclinical stage
  • 2.3. Difference between discovery, preclinical and clinical stage deals
  • 2.4. Reasons for entering into preclinical stage partnering deals
    • 2.4.1. Licensors reasons for entering preclinical stage deals
    • 2.4.2. Licensees reasons for entering preclinical stage deals
  • 2.5. The future of preclinical stage partnering deals

Chapter 3 - Preclinical stage deal strategies and structure

  • 3.1. Introduction
  • 3.2. At what stage do companies partner?
    • 3.2.1. Partnering early in pharmaceutical / biotech
    • 3.2.1.1. Discovery and preclinical stage partnering case studies
    • 3.2.1.1.a. Case study 1
    • 3.2.1.1.b. Case study 2
    • 3.2.1.1.c. Case study 3
    • 3.2.1.1.d. Case study 4
    • 3.2.2. Partnering later in pharmaceutical/biotech
    • 3.2.2.1. Clinical stage partnering case studies
    • 3.2.2.1.a. Case study 5
    • 3.2.2.1.b. Case study 6
    • 3.2.2.1.c. Case study 7
    • 3.2.2.1.d. Case study 8
  • 3.3. Early and later stage partnering - a risk/cost comparison
  • 3.4. What do companies spend on preclinical stage partnering?
  • 3.5. Pure versus multi-component partnering deals
  • 3.6. Pure licensing agreement structure
    • 3.6.1. Example pure preclinical stage licensing agreements
    • 3.6.1.a. Case study 9
    • 3.6.1.b. Case study 10
  • 3.7. Multicomponent preclinical stage partnering agreements
    • 3.7.1. Example multicomponent preclinical stage clauses
    • 3.7.1.a. Case study 11
    • 3.7.1.b. Case study 12

Chapter 4 - Preclinical stage partnering payment strategies

  • 4.1. Introduction
  • 4.2. Preclinical stage payment strategies
  • 4.3. Payment options
    • 4.3.1. Headline values
    • 4.3.2. Upfront payments
    • 4.3.2.1. Conditionality of upfront payments
    • 4.3.3. Loans
    • 4.3.4. Convertible loans
    • 4.3.5. Equity
    • 4.3.6. R&D funding
    • 4.3.7. Licensing fees
    • 4.3.8. Milestone payments
    • 4.3.9. Royalty payments
    • 4.3.9.1. Issues affecting royalty rates
    • 4.3.9.2. Royalties on combination products
    • 4.3.9.2.a. Case study 13
    • 4.3.9.3. Guaranteed minimum/maximum annual payments
    • 4.3.9.4. Royalty stacking
    • 4.3.9.5. Royalties and supply/purchase contracts
    • 4.3.10. Quids
    • 4.3.11. Option payments

Chapter 5 - Trends in preclinical stage deal making

  • 5.1. Introduction
  • 5.2. Preclinical stage partnering over the year
    • 5.2.1. Attributes of preclinical deals
  • 5.3. Preclinical stage partnering by deal type
  • 5.4. Preclinical stage partnering by disease type
  • 5.5. Partnering by preclinical stage technology type
  • 5.6. Preclinical stage partnering by most active company, 2020 - 2025

Chapter 6 - Payment terms for preclinical stage partnering

  • 6.1. Introduction
  • 6.2. Guidelines for preclinical stage payment terms
    • 6.2.1. Upfront payments
    • 6.2.2. Milestone payments
    • 6.2.3. Royalty payments
  • 6.3. Preclinical stage payment terms - deal data analysis
    • 6.3.1. Public data
    • 6.3.2. Survey data
  • 6.4. Payment terms analysis
    • 6.4.1. Preclinical stage headline values
    • 6.4.2. Preclinical stage deal upfront payments
    • 6.4.3. Preclinical stage deal milestone payments
    • 6.4.4. Preclinical stage royalty rates

Chapter 7 - Leading preclinical stage deals

  • 7.1. Introduction
  • 7.2. Top preclinical stage deals by value

Chapter 8 - Top 25 most active preclinical stage dealmakers

  • 8.1. Introduction
  • 8.2. Top 25 most active preclinical stage dealmakers

Chapter 9 - Preclinical stage partnering contracts directory

  • 9.1. Introduction
  • 9.2. Preclinical stage deals with contracts 2020 - 2025

Chapter 10 - Preclinical stage deal making by development stage

  • 10.1. Introduction
  • 10.2. Deals by preclinical stage

Appendices

  • Appendix 1 - Preclinical stage dealmaking by companies A-Z
  • Appendix 2 - Preclinical stage dealmaking by industry sector
  • Appendix 3 - Preclinical stage dealmaking by stage of development
  • Appendix 4 - Preclinical stage dealmaking by therapy area
  • Appendix 5 - Preclinical stage dealmaking by technology type
  • About Biopharma Research Ltd
  • Current Partnering
  • Current Agreements
  • Recent titles from Current Partnering

Table of figures

  • Figure 1: Definition of discovery, preclinical and clinical phases in dealmaking
  • Figure 2: Components of the pure licensing deal structure
  • Figure 3: Payment options for preclinical stage partnering deals
  • Figure 4: Issues affecting royalty rates
  • Figure 5: Preclinical stage partnering frequency 2020 - 2025
  • Figure 6: Preclinical stage partnering by deal type since 2020
  • Figure 7: Preclinical stage partnering by disease type since 2020
  • Figure 8: Preclinical stage partnering by technology type since 2020
  • Figure 9: Top 25 most active preclinical stage dealmakers, 2020 - 2025
  • Figure 10: Review of upfront payments for preclinical stage deals
  • Figure 11: Review of milestone payments for preclinical stage deals
  • Figure 12: Review of royalty payments for preclinical stage deals
  • Figure 13: Preclinical stage deals with a headline value
  • Figure 14: Preclinical stage deals with an upfront value
  • Figure 15: Preclinical stage deals with a milestone value
  • Figure 16: Preclinical stage deals with a royalty rate value
  • Figure 17: Top preclinical stage deals by value since 2020
  • Figure 18: Most active preclinical stage dealmakers 2020 - 2025